News | Congenital Heart | June 30, 2016

CorMatrix Cardiovascular Treats First Patients with Tyke Product for Neonates and Infants

Extracellular matrix now an alternative for congenital heart defect repairs in smaller structures

Cormatrix Cardiovascular, Tyke ECM, extracellular matrix, neonates and infants

June 30, 2016 — CorMatrix Cardiovascular Inc. announced the treatment of the first patients using its CorMatrix Tyke, a product specifically designed and cleared for cardiac tissue repairs in neonates and infants. The product received U.S. Food and Drug Administration (FDA) 510(k) clearance in February 2016.

CorMatrix Tyke is intended for use in neonates and infants for repair of pericardial structures, as an epicardial covering for damaged or repaired cardiac structures, as a patch material for intracardiac defects, septal defects and annulus repair, suture-line buttressing, and cardiac repair. Tyke is made of two layers of CorMatrix ECM (extracellular matrix) as compared to the four layers of the current CorMatrix ECM for Cardiac Tissue Repair, therefore providing a thinner product for smaller repairs.

Frank Scholl, M.D., chief, pediatric and congenital heart surgery and surgical director, pediatric heart transplant, and Steven Bibevski, M.D., pediatric and congenital cardiac surgeon, both at Joe DiMaggio Children’s Hospital in Hollywood, Fla., were the first to implant the CorMatrix Tyke ECM device. The company is implementing a phased commercial launch of the device involving approximately 20 pediatric centers who will be trained and certified to receive the device.

Tyke was developed as an alternative to synthetic grafts or patches, and for complex reconstructive surgeries in neonates and infants with congenital heart defects (CHD).

Scholl noted, “The availability of Tyke and its two-ply construction will allow us the ability to repair the tiniest structures in the most delicate and tiniest of newborn babies, and achieve a more accurate — and hopefully — more durable repair. We are excited about the future Tyke provides for our most fragile patients.”

The American Academy of Pediatrics and the Congenital Heart Public Health Consortium (CHPHC) estimates congenital heart defects are the most common birth defects. Nearly 1 of every 100 babies is born with a CHD and each year, approximately 40,000 babies are born in the United States with a congenital heart defect. Most CHD-related surgical procedures require the use of prosthetic material for reconstruction of intracardiac and extra cardiac structures. Several different biological and prosthetic materials are commonly used in surgery including autologous pericardium, preserved homograft, bovine pericardium and polytetrafluoroethylene. None of these alternatives represents the ideal prosthetic tissue, which should be pliable and easy to handle, resistant to calcification or shrinkage. Most importantly, it should have growth potential and should not induce formation of scar tissue.¹

For more information: www.cormatrix.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
AHA and ACC Publish New Data Dictionary for Ambulatory EHRs in Pediatric and Congenital Cardiology
News | Congenital Heart| July 19, 2017
July 19, 2017 — The American Heart Association (AHA) and the American College of Cardiology (ACC) recently published
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Novel Approach May Improve Valve Function in Some Patients

Image courtesy of Messas, et al. JACC Basic to Translational Medicine.

News | Heart Valve Technology| June 30, 2017
June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthet
Mitralign Announces First European Subject Enrolled in SCOUT II Study of Trialign System
News | Heart Valve Technology| June 27, 2017
Mitralign Inc. announced the commencement of its SCOUT II study in Europe, with the Trialign System for the treatment...
New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Overlay Init